Revolutionary Blood Test Offers Highly Accurate Predictions on Stroke Recovery Outcomes

According to a groundbreaking study conducted by the University of Gothenburg, a highly sensitive blood test that can reflect brain damage after an instance of acute ischemic stroke, and predict functional outcome, has been uncovered. This discovery is predicted to have considerable significance in the future.

Tau Proteins Revealed in Blood Test

Previous research led by Professors Kaj Blennow and Christina Jern of Sahlgrenska Academy at the University of Gothenburg had developed a new blood test that measures a certain protein in the body, known as BD-tau (Brain-derived tau), which is identified with the breakdown of neurons in the central nervous system during Alzheimer's disease.

This prior discovery is integral for developing future tools to monitor the progression of Alzheimer's. The goal of the current study was to investigate if this biomarker could likewise denote neuronal injury after acute ischemic stroke - the most common type of stroke, caused by insufficient oxygen supply to the brain due to a blood clot.

Implications for Patient Outcome

The study concluded that elevated blood levels of BD-tau during the acute phase of an ischemic stroke increased the risk of more serious outcomes three months later in the studied group of more than 800 stroke patients.

These results discard other impactful clinical variables widely understood to best predict outcome after an ischemic stroke, such as age and stroke severity, based on the esteemed NIH Stroke Scale. Adjustments were also made for gender and the day the blood sample was taken.

The Study's Lead Contributors

Tara Stanne, an Associate Professor and stroke researcher at the Department of Laboratory Medicine, and Fernando Gonzalez-Ortiz, a doctoral student at the Department of Psychiatry and Neurochemistry and a medical doctor at the Sahlgrenska University Hospital, were the study's first authors.

Potential for Future Clinical Application

Presently, no blood-based biomarkers exist which accurately reflect acute neuronal injury after a stroke or predict clinical outcomes in stroke patients. This makes the research findings all the more significant.

Gonzalez-Ortiz reported that the study is the inaugural report of a blood-based biomarker that is specific to acute neuronal injury in the brain after an ischemic stroke. Stanne added that BD-tau works as a biomarker for most types of ischemic strokes, signaling its high potential for clinical implementation in the future.

The Need for Further Research

The research team stipulates that more extensive studies are necessary to validate these results, as well as research with repeated blood sampling to determine the ideal day for sample collection following the onset of an acute stroke - targeting a prediction of the clinical outcome.